West Pharmaceutical Services, Inc. (WST)
NYSE: WST · Real-Time Price · USD
354.07
+5.47 (1.57%)
Aug 7, 2026, 4:00 PM EDT - Market closed
WST Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 435.8 | 791.3 | 484.6 | 853.9 | 894.3 | 762.6 |
Cash & Short-Term Investments | 435.8 | 791.3 | 484.6 | 853.9 | 894.3 | 762.6 |
Cash Growth | -14.50% | 63.29% | -43.25% | -4.52% | 17.27% | 23.90% |
Accounts Receivable | 712 | 574.4 | 552.5 | 512 | 507.4 | 489 |
Inventory | 447.4 | 443.9 | 377 | 434.7 | 414.8 | 378.4 |
Other Current Assets | 212.3 | 168.6 | 124 | 135.8 | 103 | 112 |
Total Current Assets | 1,808 | 1,978 | 1,538 | 1,936 | 1,920 | 1,742 |
Net Property, Plant & Equipment | 1,791 | 1,843 | 1,686 | 1,513 | 1,263 | 1,127 |
Other Intangible Assets | 6.4 | 7.7 | 10.8 | 15.1 | 18.4 | 23 |
Goodwill | 108.7 | 109.9 | 106 | 108.5 | 107.3 | 109.9 |
Long-Term Investments | 207.7 | 212.3 | 202.1 | 210 | 204.9 | 207.7 |
Other Long-Term Assets | 155.1 | 118.5 | 100.3 | 47 | 104 | 104.4 |
Total Assets | 4,076 | 4,270 | 3,643 | 3,830 | 3,617 | 3,314 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 252.7 | 253.7 | 239.3 | 242.4 | 215.4 | 232.2 |
Accrued Expenses | 131.1 | 135.9 | 73.5 | 105.9 | 76.8 | 116.3 |
Short-Term Debt | - | - | - | 134 | 2.2 | 44.2 |
Current Portion of Leases | 20.9 | 22.7 | 17.9 | 17.7 | 16 | 9.3 |
Other Current Liabilities | 235.8 | 242.6 | 219.7 | 171.8 | 208.6 | 192.1 |
Total Current Liabilities | 640.5 | 654.9 | 550.4 | 671.8 | 519 | 594.1 |
Long-Term Debt | 202.9 | 202.8 | 202.6 | 72.8 | 206.7 | 208.8 |
Long-Term Leases | 88.3 | 95.6 | 81.8 | 84.5 | 93 | 63 |
Other Long-Term Liabilities | 154.5 | 140.7 | 126.3 | 119.4 | 113.2 | 112.5 |
Total Long-Term Liabilities | 445.7 | 439.1 | 410.7 | 276.7 | 412.9 | 384.3 |
Total Liabilities | 1,086 | 1,094 | 961.1 | 948.5 | 931.9 | 978.4 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 18.8 | 18.8 | 18.8 | 18.8 | 18.8 | 18.8 |
Treasury Stock | -1,512 | -1,112 | -1,057 | -637.6 | -370.9 | -229.5 |
Additional Paid-in Capital | - | - | 22.1 | 120.2 | 232.2 | 249 |
Accumulated Other Comprehensive Income | -140.4 | -105.5 | -258.1 | -143.8 | -183 | -159.6 |
Retained Earnings | 4,624 | 4,375 | 3,957 | 3,523 | 2,988 | 2,457 |
Shareholders' Equity | 2,990 | 3,176 | 2,682 | 2,881 | 2,685 | 2,335 |
Total Liabilities & Equity | 4,076 | 4,270 | 3,643 | 3,830 | 3,617 | 3,314 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 312.1 | 321.1 | 302.3 | 309 | 317.9 | 325.3 |
Net Cash (Debt) | 123.7 | 470.2 | 182.3 | 544.9 | 576.4 | 437.3 |
Net Cash Growth | -40.07% | 157.93% | -66.54% | -5.46% | 31.81% | 50.90% |
Net Cash Per Share | 1.71 | 6.47 | 2.47 | 7.24 | 7.60 | 5.73 |
Book Value | 2,990 | 3,176 | 2,682 | 2,881 | 2,685 | 2,335 |
Book Value Per Share | 41.39 | 43.69 | 36.39 | 38.26 | 35.42 | 30.61 |
Tangible Book Value | 2,875 | 3,058 | 2,566 | 2,757 | 2,559 | 2,203 |
Tangible Book Value Per Share | 39.79 | 42.07 | 34.81 | 36.62 | 33.76 | 28.87 |